BONE MARROW & SENTINEL NODE MICROMETASTASES IN BREAST CA

骨髓

• 批准号: 6090215
• 负责人: RICHARD JAMES COTE
• 金额: $ 45.57万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-06-20 至 2005-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6090215
• 关键词: antitumor antibody; biomarker; bone marrow neoplasms; breast neoplasms; clinical research; diagnosis design /evaluation; female; human subject; lymph node neoplasm; metastasis; monoclonal antibody; neoplasm /cancer immunodiagnosis; neoplasm /cancer relapse /recurrence; neoplastic process; women's health

DESCRIPTION: (Adapted from the investigator's abstract) Breast cancer is the most common cancer and the second leading cause of cancer deaths among women. The majority of patients present with operable disease. In fact, most patients with node-negative disease will be cured by surgical resection of their tumor alone. However, due to proven efficacy, most patients with invasive breast cancer will undergo a complete axillary dissection for lymph node evaluation, and are considered candidates for adjuvant (systemic) therapy. This subjects the majority of patients with node-negative disease to the expense and side effects of axillary dissection and systemic chemotherapy. Primary treatment failure is secondary to undetectable spread of tumor, and this occult tumor is the target of adjuvant therapy. He has developed extremely sensitive methods for the detection of occult metastases in bone marrow (BM) and regional lymph nodes in patients with breast cancer. Studies from their laboratory and others strongly suggest that the presence of occult regional and systemic metastases are associated with increased recurrence and decreased survival. Furthermore, he has shown that the identification and analysis of the sentinel lymph node (SLN, the first lymph node draining the tumor bed) may reduce the need for complete axillary dissection, particularly in patients with node-negative disease. Their central hypothesis is that the presence of occult metastases to BM and SLN in patients with early stage breast cancer identifies patients at increased risk of recurrence and death, and identifies the specific target of adjuvant chemotherapy. The specific aims are: (1) To identify and quantitate occult metastases in BM and SLN of patients with breast cancer. This study will be organized by the NIH/NCI funded American College of Surgeons Oncology Group (ACOS-OG), (protocol Z0010). (2) Because they understand the difficulties of current methods to detect occult metastases, he has developed and will evaluate novel imaging and molecular methods for the detection of occult metastases. (3) To evaluate, through the ACOS-OG data management and follow up capabilities, the clinical significant of occult metastases to BM and SLN. This study will provide the essential correlative research component for the ACOS-OG multi-center clinical trial Z0010, and should provide definitive evidence regarding the use of occult metastasis detection in patients with breast cancer. The detection of occult metastases in BM and SLN, in place of more radical axillary dissection, could allow for more specific yet less invasive assessment of patient risk, and redefine the surgical and systemic treatment options for patients with breast cancer.

描述：（根据研究者的摘要改编）乳腺癌是 女性最常见的癌症和癌症死亡的第二大原因。 大多数患者患有可手术疾病。实际上，大多数患者 淋巴结疾病将通过手术切除肿瘤来治愈 独自的。但是，由于证明的功效，大多数浸润性乳房患者 癌症将进行完整的腋窝解剖以进行淋巴结评估， 被认为是辅助（全身）治疗的候选者。这个主题 大多数淋巴结疾病的患者都达到费用和侧面 腋窝解剖和全身化疗的作用。初级治疗 失败是继发肿瘤的未检测到的，这种神秘的肿瘤是 辅助治疗的靶标。他开发了极其敏感的方法 用于检测骨髓（BM）和区域淋巴的神秘转移 乳腺癌患者的节点。他们的实验室和其他人的研究 强烈建议存在神秘的区域和全身转移 与复发增加和生存降低有关。此外， 他表明，哨兵淋巴结的识别和分析 （SLN，第一个淋巴结排出肿瘤床）可能会减少对 完全的腋窝解剖，特别是在淋巴结阴性的患者中 疾病。他们的中心假设是神秘转移的存在 早期乳腺癌患者的BM和SLN确定患者 增加复发和死亡的风险，并确定 辅助化疗。具体目的是：（1）识别和定量 乳腺癌患者BM和SLN中的神秘转移。这项研究会 由NIH/NCI资助的美国外科医生肿瘤学院组织 （ACOS-OG），（协议Z0010）。 （2）因为他们了解 当前检测神秘转移的方法，他已经开发并将评估 新型成像和分子方法检测神秘转移酶。 （3） 通过ACOS-og数据管理评估并跟进功能， 对BM和SLN的神秘转移的临床意义。这项研究会 提供ACOS-OG的基本相关研究组件 多中心临床试验Z0010，应提供明确的证据 关于在乳房患者中使用隐匿性转移检测 癌症。在BM和SLN中检测神秘转移，代替更多 根治性的腋窝解剖，可以允许更具体而又较少的侵入性 评估患者风险，并重新定义手术和全身治疗 乳腺癌患者的选择。